Author + information
- Julie Damp, MD∗ ( and )
- Dennis M. McNamara, MD, MS
- ↵∗Vanderbilt University, 1215 21st Avenue South, MCE 5th Floor South Tower, Nashville, Tennessee 37232
We read with appreciation Dr. Timpka’s comments on our paper (1). Dr. Timpka points out the important concept of an association of body mass index (BMI) with levels of Relaxin-2 during pregnancy and with left ventricular ejection fraction at 12 months in peripartum cardiomyopathy (PPCM). In our study population of patients with PPCM, there was not a clear correlation between BMI and Relaxin-2 levels, although this may have been caused, in part, by the relatively small number of patients. As Dr. Timpka points out, our investigator group is currently exploring the relationship further between BMI and recovery in this cohort of patients with PPCM. We acknowledge BMI as a potential confounder in our reported analysis in the relationship between Relaxin-2 and recovery and agree that this warrants further study. Future study would most ideally be done in larger cohorts and with BMI data before pregnancy, during pregnancy, and during follow-up.
Please note: Both authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- 2016 American College of Cardiology Foundation